A Medicare-covered tissue CGP test with an
AI-powered scoring algorithm that improves
PD-L1 detection by >20% in NSCLC.1,2*
Order from the same form as liquid with results in 2-3 weeks.1†
Important Note: The Guardant360 TissueNext and Guardant Galaxy PD-L1 tests were developed, and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity testing. These tests have not been cleared or approved by the US FDA.
Covers clinically relevant biomarkers.1-3
Process samples with as low as 10% tumor fraction.
Home Guardant Infinity™ for HCPs Treatment Selection Monitoring and MRD Assessment Guardant Infinity™ for BioPharma
AI, artificial intelligence; CGP, comprehensive genomic profiling; NSCLC, non-small cell lung cancer;
PD-L1, programmed cell death ligand 1.
*Compared to manual pathologist interpretation in the most challenging cases of NSCLC.²
†From sample receipt to results. Confirmation of medical necessity is required if Guardant360 TissueNext is ordered with another Guardant Health profiling test.